Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Victor L. Serebruany"'
Publikováno v:
TH Open, Vol 05, Iss 04, Pp e503-e506 (2021)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Background Cardiovascular benefits of aggressive dual antiplatelet therapy may be associated with extra risks including bleeding, cancer, and infections discovered first for prasugrel in the TRial to assess Improvement in Therapeutic Outcomes by opti
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 3140, p 3140 (2021)
Journal of Clinical Medicine
Volume 10
Issue 14
Journal of Clinical Medicine
Volume 10
Issue 14
The potential link between antiplatelet agents and anticoagulants with excess cancer deaths (CD) was reported first for prasugrel (TRITON, DAPT), clopidogrel (DAPT), vorapaxar (TRACER), apixaban (APPRAISE-2), and later ticagrelor (PEGASUS). However,
Publikováno v:
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 02, Iss 01, Pp e28-e32 (2018)
TH Open, Vol 02, Iss 01, Pp e28-e32 (2018)
Whether aggressive prolonged dual antiplatelet therapy (DAPT) promotes solid cancer risks remains a critical unsolved issue. Since the evidence from randomized trials, affiliated U.S. Food and Drug Administration (FDA) reviews, meta-analyses, and nat
Publikováno v:
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 01, Iss 02, Pp e101-e105 (2017)
TH Open, Vol 01, Iss 02, Pp e101-e105 (2017)
Background The U.S. Food and Drug Administration (FDA) Adverse Event (AE) Reporting System (FAERS) is a global passive surveillance repository requiring mandatory updates by pharmaceutical manufacturers. Oral antiplatelet agents (OAAs) including aspi
Autor:
Vasily Cherepanov, Moo Hyun Kim, Thomas A. Marciniak, Victor L. Serebruany, Hector A. Cabrera-Fuentes, Oleg Litvinov
Publikováno v:
Cardiology. 138:249-253
Background: The US Food and Drug Administration Adverse Event Reporting System (FAERS) is a global passive surveillance database that relies on voluntary reporting by health care professionals and consumers as well as required mandatory reporting by
Publikováno v:
Cardiology. 138:201-206
Background: The optimal dosing of novel oral P2Y12 receptor platelet inhibitors such as prasugrel or ticagrelor is unclear and especially challenging in East Asians. We hypothesize that half-dose prasugrel and ticagrelor may be sufficient for long-te
Autor:
Jong Sung Park, Long Zhe Guo, Victor L. Serebruany, Moo Hyun Kim, Tae Ho Park, Cai De Jin, Michael S. Lee, Young Rak Cho, Eun-Seok Shin, Soe Hee Ann, Kyungil Park
Publikováno v:
International Journal of Cardiology. 222:639-644
The impact of thienopyridine reloading on clinical outcomes, and residual high platelet reactivity (HPR) is unclear. We sought to compare the HRP-related effect of prasugrel and clopidogrel reloading in the already clopidogrel-loaded patients undergo
Publikováno v:
International Journal of Cardiology. 195:104-110
Background ST-elevated myocardial infarction (STEMI) holds the highest early mortality among patients with acute coronary syndromes. Despite numerous claims of clinical benefits and superiority over clopidogrel, there are no head-to-head outcome rand
Publikováno v:
The American Journal of Cardiology. 116:969-972
The impact of antithrombotics on cancer is currently under intense investigation because of the excess of solid cancers in trials after thienopyridines such as TRITON (prasugrel), DAPT (prasugrel and clopidogrel), PAR-1 thrombin antagonist in TRACER
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy. 4(3)